|
Days after Trump took office, the Health and Human Services Department began purging all references to diversity, equity, and inclusion (DEI) from the websites of its agencies. Those efforts were supposed to target DEI initiatives focused on hiring practices, communications, and social issues. But supporters of clinical trial diversity say the policy has nothing to do with DEI in that sense. Instead, it aims to ensure that clinical trials enroll people who are similar to the patients who would use the drugs and medical devices being tested.
Congressional Republicans seem to agree. Last month, the Republican-controlled House passed a bill, mostly along party lines, to fund the Food and Drug Administration. It was accompanied by a report that, while not legally binding, tells agency officials what congressional appropriators expected of them. A section of that bill deals with trial diversity.
A couple of years ago, ICER-developed a Clinical Trial Diversity Rating (CDR) tool for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall rating. Groups such as Health Technology Assessment bodies, clinical trial regulators, policymakers, journal editors, and individual researchers can use this tool to examine, monitor, and improve diversity in clinical trials.
|